P. López-Saura

发表

Epidermal growth factor intralesional infiltrations can prevent amputation in patients with advanced diabetic foot wounds

Jorge Amador Berlanga Acosta, W. Savigne, Calixto Valdez, 2006, International wound journal.

Intra‐lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo‐controlled, double‐blind study

W. Savigne, P. López-Saura, J. Fernández-Montequín, 2009, International wound journal.

Angiographic patency study of an albumin-free recombinant streptokinase formulation in acute myocardial infarction.

P. López-Saura, B. Betancourt, L. Llerena, 2004, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

Regression of Infancy Hemangiomas with Recombinant IFN-α2b

P. López-Saura, G. Garmendía, N. Miranda, 2001 .

Adjuvant interferon gamma in patients with drug – resistant pulmonary tuberculosis: a pilot study

P. López-Saura, C. Valenzuela-Silva, R. Suárez-Méndez, 2004, BMC infectious diseases.

Adjuvant Interferon Gamma in the Management of Multidrug - Resistant Tuberculosis

P. López-Saura, C. Valenzuela-Silva, R. Suárez-Méndez, 2012 .

Adjuvant interferon gamma in patients with pulmonary atypical Mycobacteriosis: A randomized, double-blind, placebo-controlled study

L. González-Méndez, P. López-Saura, C. Valenzuela-Silva, 2008, BMC infectious diseases.

Streptokinase for the Treatment of Acute Ischaemic Stroke

P. López-Saura, B. Betancourt, Jaime Parellada-Blanco, 2003, CNS drugs.

Therapeutic angiogenesis following intramuscular gene transfer of vascular endothelialgrowth factor 121 in a dog model of hindlimb ischemia

L. Sorell, P. López-Saura, Luís Herrera, 2003 .

Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study

P. López-Saura, C. A. González-Delgado, C. Valenzuela-Silva, 2010, BMC pharmacology.

Interferon alpha-2 b and ribavirin as combined therapy for chronic hepatitis C in Cuba : National Program

P. López-Saura, E. García‐Iglesias, Enrique R Arús-Soler, 2012 .

Abstract

Ó., P. López-Saura, J. Reyes, 2003 .

Thrombolysis as first choice therapy in prosthetic heart valve thrombosis. A study of 68 patients

P. López-Saura, B. Betancourt, F. Cáceres-Lóriga, 2006, Journal of Thrombosis and Thrombolysis.

Growth-hormone-releasing peptide 6 (GHRP6) prevents oxidant cytotoxicity and reduces myocardial necrosis in a model of acute myocardial infarction.

J. S. Alba, P. López-Saura, G. Guillén, 2007, Clinical science.

Use of growth-hormone-releasing peptide-6 (GHRP-6) for the prevention of multiple organ failure.

R. Playford, R. Goodlad, Subrata Ghosh, 2006, Clinical science.

Attenuation of internal organ damages by exogenously administered epidermal growth factor (EGF) in burned rodents.

P. López-Saura, J. Berlanga, J. Lodos, 2002, Burns : journal of the International Society for Burn Injuries.

Prophylactic use of epidermal growth factor reduces ischemia/reperfusion intestinal damage.

R. Playford, J. Boyle, P. López-Saura, 2002, The American journal of pathology.

Immunoglobulin E-Dependent Regulation of the CCR3 Chemokine Receptor by Interferon-Gamma in Atopic Asthmatics

P. López-Saura, C. Valenzuela-Silva, I. Bello-Rivero, 2008, International Archives of Allergy and Immunology.

Clinical and immunological evaluation of asthmatic patients in a double blind treatment protocol with transfer factor

P. López-Saura, J. Jiménez, P. Saura, 1995 .

Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: A parallel, randomized, double blind study

P. López-Saura, C. Valenzuela-Silva, Raúl Herrera-Valdés, 2005, BMC nephrology.

Bioequivalence of two recombinant granulocyte colony-stimulating factor formulations in healthy male volunteers.

P. López-Saura, C. A. González-Delgado, C. Valenzuela-Silva, 2005, Biopharmaceutics & drug disposition.

Bioequivalence of Two Recombinant Interferon α-2b Liquid Formulations in Healthy Male Volunteers

P. López-Saura, C. A. González-Delgado, C. Valenzuela-Silva, 2004 .

In vitro interferon gamma regulation of CCR-3 mRNA expression in peripheral blood leukocytes from atopic asthmatics

P. López-Saura, E. Blanco, J. Saldivar, 2001, Clinical and Experimental Medicine.

Use of recombinant interferon gamma in pediatric patients with advanced juvenile chronic arthritis

P. López-Saura, G. Varela, V. Hernández, 1998, Biotherapy.

Comparative Pharmacokinetics and Pharmacodynamics of Two Recombinant Human Interferon Alpha-2b Formulations Administered Intramuscularly in Healthy Male Volunteers

P. López-Saura, José L. Rodríguez, J. Duconge, 2000 .

Recombinant streptokinase vs phenylephrine-based suppositories in acute hemorrhoids, randomized, controlled trial (THERESA-3).

P. López-Saura, C. Valenzuela-Silva, F. Hernández-Bernal, 2014, World journal of gastroenterology.

Cuban interferon alpha-2 b . Thirty years as an effective and safe drug

P. López-Saura, H. Nodarse-Cuní, 2017 .

CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical research

D. Gomez, D. Alonso, Y. Perera, 2011, Molecular and Cellular Biochemistry.

CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo

D. Alonso, O. Mendoza, Y. Perera, 2008, Molecular and Cellular Biochemistry.

Growth-hormone-releasing peptide 6 ( GHRP 6 ) prevents oxidant cytotoxicity and reduces myocardial necrosis in a model of acute myocardial infarction

J. S. Alba, P. López-Saura, G. Guillén, 2007 .

Epidermal growth factor reduces multiorgan failure induced by thioacetamide

R. Playford, P. López-Saura, D. Floyd, 2001, Gut.

Detrimental impact of acute and chronic glucose burden in wound-healing cells : fibroblasts , myofibroblasts and vascular precursor cells

P. López-Saura, J. Berlanga-Acosta, Marianela García-Siverio, 2012 .

Analytical characterization and purification of plasma membrane from cultured hepatoma cells (HTC cells).

P. Tulkens, P. López-Saura, P. Sauvage, 1981, Biochimica et biophysica acta.

Immunogenicity of a recombinant, yeast-derived, anti-hepatitis-B vaccine after alternative dosage and schedule vaccination in Pakistani children.

P. López-Saura, C. Valenzuela-Silva, S. Maqbool, 2005, Vaccine.

TNF-α and IL-10 downregulation and marked oxidative stress in Neuromyelitis Optica

P. López-Saura, J. Cabrera-Gomez, C. Valenzuela-Silva, 2009, Journal of Inflammation.

Immunogenicity of 10 and 20 μg hepatitis B vaccine in a two-dose schedule

S. S. Hasnain, Z. Abbas, P. López-Saura, 2003 .

Characterization of the immunoreactivity of anti-interferon alpha antibodies in myasthenia gravis patients. Epitope mapping.

P. López-Saura, I. García, Jesús Pérez, 2004, Journal of autoimmunity.

Epidermal growth factor in the treatment of radiogenic proctitis

P. López-Saura, M. Pascual, F. Hernández-Bernal, 2009 .

Long-term treatment with recombinant interferon alpha-2b prolongs survival of asymptomatic HIV-infected individuals

P. López-Saura, J. Rivero, J. Cuervo, 1997, Biotherapy.

A multicenter, randomized, double-blind clinical trial examining the effect of oral human recombinant epidermal growth factor on the healing of duodenal ulcers.

P. López-Saura, A. Palomino, F. Hernández-Bernal, 2000, Scandinavian journal of gastroenterology.

Medical Practice Confirms Clinical Trial Results of the Use of Intralesional Human Recombinant Epidermal Growth Factor in Advanced Diabetic FootUlcers

P. López-Saura, J. Fernández-Montequín, C. Valenzuela-Silva, 2013 .

Intralesional Human Recombinant Epidermal Growth Factor for the Treatment of Advanced Diabetic Foot Ulcer: From Proof of Concept to Confirmation of the Efficacy and Safety of the Procedure

W. Savigne, P. López-Saura, J. Fernández-Montequín, 2011 .

Epidermal growth factor in clinical practice – a review of its biological actions, clinical indications and safety implications

P. López-Saura, J. Gavilondo-Cowley, J. Berlanga-Acosta, 2009, International wound journal.

Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study

P. López-Saura, I. Bello-Rivero, Y. García-Vega, 2009, BMC Cancer.

Intralesional injections of Citoprot‐P® (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation

P. López-Saura, J. Fernández-Montequín, C. Valenzuela-Silva, 2007, International wound journal.

Analytical fractionation of cultured hepatoma cells (HTC cells).

P. Tulkens, P. López-Saura, A. Trouet, 1978, Biochimica et biophysica acta.

Immunogenicity of 10 and 20 microgram hepatitis B vaccine in a two-dose schedule.

S. S. Hasnain, Z. Abbas, P. López-Saura, 2003, Vaccine.

Treatment with type I interferons induces a regulatory T cell subset in peripheral blood mononuclear cells from multiple sclerosis patients.

P. López-Saura, J. Cabrera-Gomez, C. Valenzuela-Silva, 2008, International immunopharmacology.

Use of interferon-α in laryngeal papillomatosis: eight years of the Cuban national programme

H. Strander, P. López-Saura, R. Seijas, 1997, The Journal of Laryngology & Otology.

Interferon alpha-2b as adjuvant treatment of recurrent respiratory papillomatosis in Cuba: National Programme (1994-1999 report).

P. López-Saura, H. Nodarse-Cuní, Carmen Viada-González, 2004, The Journal of laryngology and otology.

induced by thioacetamide Epidermal growth factor reduces multiorgan failure

R. Playford, P. López-Saura, D. Floyd, 2000 .

Impacto perjudicial del exceso agudo y crónico de glucosa en células involucradas en la cicatrización: fibroblastos, miofibroblastos y células precursoras vasculares

P. López-Saura, Marianela García-Siverio, Y. Mendoza-Marí, 2012 .

Pharmacovigilance program to monitor adverse reactions of recombinant streptokinase in acute myocardial infarction

P. López-Saura, C. Valenzuela-Silva, B. Betancourt, 2005, BMC clinical pharmacology.

Safety and preliminary efficacy data of a novel Casein Kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies

D. Alonso, P. López-Saura, S. Perea, 2009, BMC Cancer.

Epidemiological characterization of acute hemorrhoidal disease in selected hospitals in Cuba (November 2011 to January 2012)

P. López-Saura, C. Valenzuela-Silva, F. Hernández-Bernal, 2014 .

Granulation Response and Partial Wound Closure Predict Healing in Clinical Trials on Advanced Diabetes Foot Ulcers Treated With Recombinant Human Epidermal Growth Factor

P. López-Saura, J. Fernández-Montequín, C. Valenzuela-Silva, 2013, Diabetes Care.

Methylglyoxal administration induces diabetes-like microvascular changes and perturbs the healing process of cutaneous wounds.

Paul J Thornalley, J. S. Alba, P. López-Saura, 2005, Clinical science.

Pharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha-2b and gamma in healthy male volunteers

P. López-Saura, C. A. González-Delgado, C. Valenzuela-Silva, 2016, BMC Pharmacology and Toxicology.

Epidermal growth factor enemas for induction of remission in left-sided ulcerative colitis

P. López-Saura, C. Valenzuela-Silva, J. Berlanga-Acosta, 2013 .

Intralesional recombinant interferon alpha-2b in Peyronie's disease.

P. López-Saura, R. Astorga, D. Contreras, 2000, Archivos espanoles de urologia.

The pro‐inflammatory environment in recalcitrant diabetic foot wounds

Jorge Amador Berlanga Acosta, W. Savigne, P. López-Saura, 2008, International wound journal.

Regression of infancy hemangiomas with recombinant IFN-alpha 2b.

P. López-Saura, G. Garmendía, N. Miranda, 2001, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Type 2 Diabetes Mellitus (T2DM): Biological Overview from Pathways to Organelles and its Translation toward a Torpid Wound Healing Process

P. López-Saura, G. Guillén-Nieto, Luís Herrera-Martínez, 2013 .

Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine ( CIGB-228 ) inWomen with High-Grade Cervical Intraepithelial Neoplasia : First-inHuman , Proof-of-Concept Trial

P. López-Saura, A. Ferrer, I. Torréns, 2014 .

Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial

P. López-Saura, A. Ferrer, I. Torréns, 2011, ISRN obstetrics and gynecology.

C-Phycocyanin ameliorates experimental autoimmune encephalomyelitis and induces regulatory T cells.

P. López-Saura, C. Valenzuela-Silva, G. Martínez-Sánchez, 2011, International immunopharmacology.

Recombinant streptokinase suppositories in the treatment of acute haemorrhoidal disease. Multicentre randomized double‐blind placebo‐controlled trial (THERESA‐2)

P. López-Saura, C. Valenzuela-Silva, F. Hernández-Bernal, 2013, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[Alpha interferon and Alzheimer's disease].

P. López-Saura, J. Cabrera-Gomez, 2000, Revista de neurologia.

C-Phycocyanin is neuroprotective against global cerebral ischemia/reperfusion injury in gerbils

P. López-Saura, G. Martínez-Sánchez, G. Pentón-Rol, 2011, Brain Research Bulletin.

Epidermal Growth Factor-mediated Prevention of Renal Ischemia / Reperfusion Injury

P. López-Saura, J. L. Calunga, E. Barber, 2005 .

Construction, purification, and characterization of a chimeric TH1 antagonist

P. López-Saura, G. Pentón-Rol, Haydee Gerónimo-Pérez, 2006, BMC biotechnology.

New alternatives for the development of vaccine preparations : contributions to the knowledge on the interaction of recombinant protein viral antigens with nucleic acids

P. López-Saura, A. Musacchio, Y. Soria, 2008 .

Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer

D. Alonso, A. Perera, P. López-Saura, 2015, British Journal of Cancer.

[Alpha interferon in the treatment of multiple sclerosis. Update and experience in Cuba].

P. López-Saura, J. Cabrera-Gomez, 1999, Revista de neurología (Ed. impresa).

Pharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha-2b and gamma in healthy male volunteers

P. López-Saura, C. A. González-Delgado, C. Valenzuela-Silva, 2016, BMC Pharmacology and Toxicology.

[Interferon alfa 2b treatment decreases histological activity in children with chronic hepatitis B].

P. López-Saura, C. Viada, B. Grá, 2002, Acta gastroenterologica Latinoamericana.

Development of a new formulation of interferons (HEBERPAG) for BCC treatment

P. López-Saura, C. Valenzuela-Silva, I. Bello-Rivero, 2013 .

Bioequivalence of two recombinant interferon alpha-2b liquid formulations in healthy male volunteers.

P. López-Saura, C. A. González-Delgado, C. Valenzuela-Silva, 2004, Drugs in R&D.

Comparative Pharmacokinetics and Pharmacodynamics of Two Recombinant Human Interferon Alpha-2b Formulations Administered Intramuscularly in Healthy Male Volunteers

P. López-Saura, José L. Rodríguez, J. Duconge, 2000 .

Increased bioavailability of IFN a 2 b modificed by chemical conjugation to a two-branched polyethyleneglycol molecule

P. López-Saura, I. García, C. Peniche, 2016 .

Epidermal growth factor intralesional infiltrations can prevent amputation in patients with advanced diabetic foot wounds

Jorge Amador Berlanga Acosta, W. Savigne, Calixto Valdez, 2006, International wound journal.

Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers

P. López-Saura, C. Valenzuela-Silva, Á. Tuero-Iglesias, 2013, BMC Pharmacology and Toxicology.

P. López-Saura, J. Fernández-Montequín, C. Valenzuela-Silva, 2009, International wound journal.

Open Access book

P. López-Saura, J. Fernández-Montequín, C. Valenzuela-Silva, 2017 .

[Recent advances in the treatment the nervous system disorders with interferon-alpha].

P. López-Saura, J. Cabrera-Gomez, 1999, Revista de neurologia.

A Multicenter, Randomized, Double-Blind Clinical Trial Examining the Effect of Oral Human Recombinant Epidermal Growth Factor on the Healing of Duodenal Ulcers

P. López-Saura, A. Palomino, W. Haedo, 2000 .